Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is a life-threatening infection transmitted primarily by triatomine bugs. Originating in rural Latin America, CD has spread globally through various transmission routes, including organ transplantation, blood transfusion, contaminated food and drink, and hereditary transfer. Millions in vulnerable stages face poverty and inadequate medical care due to unawareness and resource constraints. The acute phase presents symptoms like fever, anorexia, fatigue, and tachycardia, progressing to the chronic phase with severe health issues, including congenital heart diseases and neurological damage. It remains a neglected tropical disease recognized by the World Health Organization. Diagnosis involves serological, molecular, and parasitological tests, with challenges such as underdiagnosis. Antiparasitic medications, including Benznidazole and Nifurtimox, offer limited effectiveness, and drug resistance is emerging. Ongoing research explores new drugs, immunotherapies, gene therapy, and combination therapies. Diagnostic advances include nucleic acid amplification tests and serological tests with recombinant antigens. Vector control is crucial, focusing on insecticide use, housing improvements, and community education. Blood screening, organ transplantation screening, and prenatal interventions contribute to prevention. The disease's global burden affects millions, with challenges in endemic and non-endemic regions. Future research must address disease mechanisms, enhance diagnostic methods, explore new treatment options, and develop effective prevention strategies. Genomics, drug discovery, immunotherapy, vector control, and health system strengthening offer opportunities. Eradication potential lies in comprehensive public health strategies, targeting vectors, blood screening, and prenatal care, underscoring the need for sustained efforts and research innovations in the fight against Chagas disease.